PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 88163579 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 115 |
MARK SECTION | |
MARK | EBSOLYR (see, http://uspto.report/TM/88163579/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | EBSOLYR |
OWNER SECTION (current) | |
NAME | Janssen Sciences Ireland Unlimited Company |
MAILING ADDRESS | Barnahely |
CITY | Ringaskiddy, Co. Cork |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 732-524-2889 |
FAX | 732-524-6341 |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Janssen Sciences Ireland Unlimited Company |
MAILING ADDRESS | Barnahely |
CITY | Ringaskiddy, Co. Cork |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 732-524-2889 |
FAX | 732-524-6341 |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Cheryl L. Foytlin |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | tmus@its.jnj.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | mkirczo@its.jnj.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Cheryl L. Foytlin |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | tmus@its.jnj.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | skrulews@its.jnj.com |
DOCKET/REFERENCE NUMBER | T44224US1 |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 4 |
ONGOING EFFORT | product or service research or development |
ALLOWANCE MAIL DATE | 05/07/2019 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 1 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 125 |
TOTAL AMOUNT | 125 |
SIGNATURE SECTION | |
SIGNATURE | /clfjnj/ |
SIGNATORY'S NAME | Cheryl L. Foytlin |
SIGNATORY'S POSITION | Attorney of Record - New Jersey Bar Member |
DATE SIGNED | 03/29/2021 |
SIGNATORY'S PHONE NUMBER | 732-524-2889 |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Mon Mar 29 13:16:15 ET 2021 |
TEAS STAMP | USPTO/ESU-XX.XXX.XXX.XXX- 20210329131615038483-8816 3579-770e912b1a610c1ae359 fefabf10aff83a186ed5fc6c8 82070ac8d3b9138e786aa-DA- 16133268-2021032911365259 0318 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |